Cost-Effectiveness of Neonatal Extracorporeal Membrane Oxygenation Based on 7-Year Results From the United Kingdom Collaborative ECMO Trial
- 1 May 2006
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 117 (5) , 1640-1649
- https://doi.org/10.1542/peds.2005-1150
Abstract
OBJECTIVE. To assess the long-term cost-effectiveness of extracorporeal membrane oxygenation (ECMO) for mature newborn infants with severe respiratory failure.METHODS. A prospective economic evaluation was conducted alongside a pragmatic randomized, controlled trial in which 185 infants were randomly allocated to ECMO (n = 93) or conventional management (n = 92) and then followed up to 7 years of age. Information about their use of health services during the follow-up period was combined with unit costs (£, 2002–2003 prices) to obtain a net cost per child. The cost-effectiveness of neonatal ECMO was expressed in terms of incremental cost per additional life year gained and incremental cost per additional disability-free life year gained. The nonparametric bootstrap method was used to present cost-effectiveness acceptability curves and net benefit statistics at alternative willingness-to-pay thresholds held by decision-makers for an additional life year and for an additional disability-free life year.RESULTS. Over 7 years, neonatal ECMO was effective at reducing known death or severe disability. Mean health service costs during the first 7 years of life were £30270 in the ECMO group and £10229 in the conventional management group, generating a mean cost difference of £20041 that was statistically significant. The incremental cost per life year gained was estimated at £13385. The incremental cost per disability-free life year gained was estimated at £23566. At the notional willingness-to-pay threshold of £30000 for an additional life year, the probability that neonatal ECMO is cost-effective at 7 years was estimated at 0.98. This translated into a mean net benefit of £24362 for each adoption of neonatal ECMO rather than conventional management.CONCLUSIONS. This study provides rigorous evidence of the cost-effectiveness of neonatal ECMO during childhood.Keywords
This publication has 26 references indexed in Scilit:
- United Kingdom Collaborative Randomized Trial of Neonatal Extracorporeal Membrane Oxygenation: Follow-up to Age 7 YearsPediatrics, 2006
- Resource use and health outcomes of paediatric extracorporeal membrane oxygenationArchives of Disease in Childhood: Fetal & Neonatal, 2005
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Methodological issues raised by preference‐based approaches to measuring the health status of childrenHealth Economics, 2003
- Extracorporeal membrane oxygenation for severe respiratory failure in newborn infantsPublished by Wiley ,2002
- Analysis of cost data in randomized trials: an application of the non-parametric bootstrapStatistics in Medicine, 2000
- A cost analysis of neonatal care in the UK: results from a multicentre studyJournal of Public Health, 2000
- Discounting and health benefitsHealth Economics, 1992
- Persistent Fetal Circulation and Extracorporeal Membrane OxygenationThe Lancet, 1988
- Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trialThe Journal of Pediatrics, 1985